PARP inhibitorPhase 3 trialInvestigational
Lynparza
Generic name: olaparib
How it works
Olaparib blocks the PARP enzyme, which is involved in DNA repair, thereby sensitizing cancer cells to DNA damage.
Cancer types
Efficacy
Studies show that olaparib can improve response rates and overall survival in patients with metastatic colorectal cancer harboring BRCA1/2 mutations.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| New Compound Disrupts Cancer Gene Expression | Colorectal Cancer | lab-study | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Studying Olaparib in Metastatic Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Olaparib Study for Patients Who Have Completed Previous Oncology Trials | Breast Cancer | phase-3 | — | Source → |
| Testing Olaparib with Radium-223 in Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Cediranib and Olaparib Combination Therapy for Advanced Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing Cediranib and Olaparib in Ovarian and Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing Cediranib and Olaparib in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing New Treatments for Women with Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Testing a Combination of Two Drugs for Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing FPI-2265 and Olaparib for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Evaluating Olaparib in Chinese Patients with Advanced Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Testing Olaparib and Pembrolizumab for Advanced Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Olaparib for Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leukemia | phase-2 | — | Source → |
| Researchers Identify New Target to Enhance Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Curcumin Analogue and Olaparib Combination Shows Promise in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise in Treating Triple-Negative Breast Cancer | Breast Cancer | lab-study | The combination of Olaparib and Exemestane was able to achieve enhanced tumor growth inhibition in a murine xenograft model, greater than either drug employed as a single agent. | Source → |
| TTK protein linked to resistance in ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Olaparib plus bevacizumab in older ovarian cancer patients: manageable safety and quality of life | Ovarian Cancer | phase-3 | Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points and +4.82 points, respectively). | Source → |
| Combining Cancer Treatments May Help Prostate Cancer Patients | Prostate Cancer | lab-study | — | Source → |
| Combining Cancer Drugs Boosts Immune Response in Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| DRG2 levels predict response to PARP inhibitors in prostate cancer cells | Prostate Cancer | lab-study | — | Source → |
| Olaparib Monotherapy Shows Promise in Lung Cancer Treatment | Lung Cancer | meta-analysis | Olaparib monotherapy increased progression-free survival (PFS) level [ES= 7.76; 95% CI= 0.16 to 1.36; P=0.208]. | Source → |
| Olaparib Therapy Side Effects in UAE Patients | Breast Cancer | observational | — | Source → |
| Olaparib vs Nonplatinum Chemotherapy in Ovarian Cancer | Ovarian Cancer | phase-3 | Overall survival with olaparib was similar to chemotherapy (median 34.9 and 32.9 months, respectively). | Source → |
| Combining drugs may improve ovarian cancer treatment | Ovarian Cancer | lab-study | The combined treatment allows a substantial dose reduction of olaparib rendering a strong synergistic effect. | Source → |
| Olaparib Maintenance Therapy Shows Promise in Ovarian Cancer | Ovarian Cancer | observational | The 1-year progression-free survival rate was 75.2% (95% CI, 63.4 to 89.2), and the median PFS was 21.0 months (95% CI, 13.8 to 28.2). | Source → |
| Combining Cancer Drugs May Improve Treatment for Advanced Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Rare Lung Disease Linked to Cancer Treatment | Breast Cancer | observational | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| gBRCA Testing and Olaparib in Pancreatic Cancer | Pancreatic Cancer | observational | The best responses to platinum-based chemotherapy included a complete response in one patient (12.5%) and a partial response in seven patients (87.5%). | Source → |
| Combination Cediranib and Olaparib Shows Activity in Ovarian Cancer | Ovarian Cancer | phase-2 | In platinum-sensitive ovarian cancer, the overall response rate was 77.1% and median progression-free survival was 16.4 months. | Source → |
| Olaparib Maintenance Therapy in Ovarian Cancer: Biomarker Analysis | Ovarian Cancer | phase-3 | HRD-positive patients displayed greater median PFS [17.9 months (95% CI: 14.5-22.1)] than HRD-negative patients [9.2 months (95% CI: 7.5-13.8)]. | Source → |
| Olaparib Maintenance Therapy for Ovarian Cancer: A Study at Kurume University Hospital | Ovarian Cancer | observational | The median progression-free survival was 8.9 months, and the median overall survival was 27.1 months. | Source → |
| Pancreatic Cancer Treatment Shows Promise in Rare Genetic Case | Ovarian Cancer | observational | — | Source → |
| CRABP2 May Reduce Effectiveness of Cancer Treatment Olaparib | Ovarian Cancer | lab-study | — | Source → |
| Inhibiting FSP1 Enhances Olaparib Sensitivity in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Combining Olaparib and CDK12-IN-3 to Treat Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Possible Cause of Cancer Treatment Resistance | Pancreatic Cancer | lab-study | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| Combining drugs may help overcome resistance to ovarian cancer treatment | Ovarian Cancer | lab-study | — | Source → |
| Measuring PARP Inhibitors in Ovarian Cancer Patients | Ovarian Cancer | lab-study | — | Source → |
| Choosing the Right Maintenance Therapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.